Clinical supply milestone reached for triple-negative breast cancer treatment12 Jun 2019
PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.
Phoenix Molecular Designs (PhoenixMD), a privately-held biotechnology company designing precise cancer therapeutics targeting essential kinases, has announced the completion of clinical trial supply manufacture for PMD-026.
PhoenixMD's lead program, PMD-026, is the first RSK inhibitor built for the treatment of triple-negative breast cancer (TNBC). The clinical trial supply was undertaken by STA Pharmaceutical (WuXi STA), a subsidiary of WuXi AppTec, and is being used to support IND-enabling toxicology studies and an upcoming Phase I/Ib study in women with breast cancer.
In March 2018, the companies entered into a major manufacturing agreement, and have since produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices. This represents a significant milestone, accelerating PhoenixMD's Phase I readiness.
To further the collaboration, WuXi STA expanded its US operations to include capsule production under GMP regulatory compliance. Dr Minzhang Chen, CEO of WuXi STA, commented: "The opportunity to enable PhoenixMD's first-in-man studies came at an opportune moment for STA's San Diego facility."
"Our partnership with WuXi STA has been critical for PhoenixMD to advance this stage of our development. Working with such a high quality, globally recognized manufacturing partner has allowed us to rapidly advance PMD-026 through IND-enabling GLP toxicology studies and has enabled us to be ready to initiate our Phase I/Ib study with high quality API in capsules," said Sandra E. Dunn, CEO of PhoenixMD. "The rapid achievement of this milestone brings us one step closer to initiating our study for women suffering from breast cancer. More specifically, metastatic triple-negative breast cancer, which is the most deadly type of breast cancer. RSK2 is a promising new drug target for the treatment of TNBC, and PMD-026 is the first drug to ever reach clinical use against this novel target."
"The secret sauce in our success – teamwork. We truly appreciate the collaborative approach and commitment that WuXi STA has brought to the PMD-026 project," notes Dr Dunn.
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk
11 Jun 2019
No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.Read more
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma
6 Jun 2019
Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.Read more
Lilly gets its hands on non-opioid pain asset
4 Jun 2019
Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.Read more
Updated clinical trial simulation software saves time and money
3 Jun 2019
One customer saves $25m and 3 years' development time in their clinical development strategy.Read more
Merck bolsters oncology pipeline with acquisition
22 May 2019
Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.Read more
Follicum files patent application for new topical formulation for hair loss
30 Apr 2019
Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.Read more
Hovione Technology acquires global rights to new pulmonary inhaler device
15 Apr 2019
The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.Read more
Isotype-specific secondary antibodies for improved signal detection
10 Apr 2019
Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.Read more
Sterling Pharma to acquire CiVentiChem in the US
9 Apr 2019
The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.Read more
Catalent expands OptiMelt hot melt extrusion capabilities
4 Apr 2019
The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation